LONDON, England and DUBLIN, Ireland, January 11 /PRNewswire-FirstCall/ -- - Trading Profitability in Line With Analysts Expectations - Significant Technological and Commercial Progress in Nanopeutics(TM) Subsidiary - Nanopeutics Entry Into the Global Consumer Woundcare, Military and the Global Blood Filtration Markets - Final Stage Negotiations With a North American Based CVH Specialist to Enter the Global Nutrition Market With a Range of Patented CVH Functional Food and Bio-Active Technologies Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets, today announces that following the commencement of first licence revenue in quarter four, analysis of initial consolidated numbers indicate that full year 2006 numbers will be in line with analysts profitability expectations. Formal full year preliminary results are scheduled for release in early April 2007. Highlights of the quarter include: - Nanopeutics, the specialist subsidiary dedicated to the commercialisation of Nanospider(TM) technology for the global woundcare markets, agrees a license bearing exclusive nanotechnology development partnership with a global leader in professional woundcare. The concept development project is ahead of agreed schedule and the successful conclusion to the development work will lead to an exclusive global royalty bearing licence and supply agreement for Nanospider(TM) based technology and specialist products. - Nanopeutics is currently finalizing negotiations on similar exclusive concept development agreements with existing companies in a number of other woundcare and related markets; specifically the global consumer woundcare, the military and the global blood filtration markets. Separate announcements are expected later this quarter. - Following last quarters preclinical trials confirming wound and dermal healing properties in a number of finalised product delivery systems Alltracel are now in late stage negotiations with a specialist anti-microbial supplier for the in-licencing of a novel anti-microbial technology for exclusive commercialization rights for the global woundcare markets: consumer, professional and military for textile, non-textile and nanofibre applications. - Following successful combination trials earlier this year and last quarter's successful development of a highly soluble derivative of Alltracel's patented cardiovascular health benefiting bioactive; subsequent commercialisation negotiations are concluding with one of the combination trial partners, a North American based CVH specialist, for the establishment of a technology and business development alliance to enter the global nutrition market with a range of patented CVH functional food and bio-active technologies. A separate statement is expected shortly. - Oralcare- continued strong oral care trade performance with business wins in all major markets Alltracel CEO Tony Richardson commented: "We are pleased at the significant progress this quarter both in terms of financial performance, technology breakthroughs and significant commercial developments. Subject to final confirmation and audit we remain comfortable with analysts' expectations of the business reaching full year profitability for the year 2006. Our oral care business continues to perform strongly and following the cessation of our exploratory discussions last month concerning the potential disposal of this division, we have progressed plans to grow this business via further investment and potential M&A activity. This quarter saw our first licence revenue and we are confident of a continued growth in sustainable profitable revenue as we transition the business to more of a licence and technology transfer business model rather than one focussed on product revenue alone." For Further Information Contact: Dublin: Denise Cronin Alltracel: +353-1-235-2162 email@example.com London: Deborah Scott Financial Dynamics: +44-(0)207-831-3113 New York: Sean Leous Financial Dynamics: +1-212-850-5626 Notes to Editors follow: Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc ("Alltracel") is a Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets. With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001. Alltracel' has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focussed on its markets. In the consumer Woundcare market m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel's patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent and is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide. Alltracel's specialist Nanotechnology subsidiary Nanopeutics(TM) (www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of Nanospider(TM) technology for the global professional and consumer woundcare markets. Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following over two years of scientific research including in vitro, pre-clinical and clinical trials, indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products. The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods. m-doc(TM) is a trademarks of Alltracel Pharmaceuticals PLC. Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by Nanopeutics s.r.o.
SOURCE Alltracel Pharmaceuticals Plc.